Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 15/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297889 | 0.78 | NOTUM (0.56) | NOTUMTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL2644943 | 0.78 | NOTUM (0.42) | NOTUMNPC1RAB9AALDH1A1HPGD | |
| SCHEMBL21241342 | 0.78 | NOTUM (0.56) | NOTUMTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL24921604 | 0.74 | NOTUM (0.50) | NOTUMTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL30050215 | 0.74 | NPSR1 (0.52) | NOTUMHPGD | |
| SCHEMBL26096222 | 0.73 | NOTUM (0.44) | NOTUMTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL1194538 | 0.72 | NOTUM (0.64) | NOTUMTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL40864 | 0.72 | KDM4E (0.46) | CA2TSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL29843360 | 0.72 | CA2 (0.40) | CA2ALDH1A1 | |
| SCHEMBL1558150 | 0.72 | CA2 (0.40) | CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | CA2 3914/4885NOTUM 3221/4885TSHR 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.